BioSpace

Your source for biopharma news and jobs

[BioSpace @biospace]

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles.
#jobmarket #biopharma #biospace
https://t.co/UmZYytOCbd

[BioSpace @biospace]

It’s not unusual for it to take unemployed biopharma professionals awhile to land new jobs. Three experts discuss when employment gaps are an issue and how to explain them to prospective employers.
#employmentgaps #biopharma #biospace
https://t.co/I1iGGe7kvF

[BioSpace @biospace]

Looking for a biopharma job? Check out our list of 12 top companies hiring life sciences professionals like you.
#nowhiring #biopharma #biospace
https://t.co/QeiPu9cj0h

[BioSpace @biospace]

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.

https://t.co/TWxyDpzTqW

[BioSpace @biospace]

Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing.

https://t.co/IQuWDlwwP9

[BioSpace @biospace]

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.

https://t.co/pFZ1kludLy

[BioSpace @biospace]

All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met.

https://t.co/yUhEk6c1Xb

[BioSpace @biospace]

Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.

https://t.co/YS7Lw9kGEx

[BioSpace @biospace]

Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly, dive into the long-overlooked hair loss space, exploring why true innovation has lagged.
https://t.co/PfzfoP84w8

[BioSpace @biospace]

FDA inspectors found that Medline, which raised billions of dollars last year, failed to prevent repeat bacterial contamination of finished drug products.

https://t.co/uprWm1svw6

[BioSpace @biospace]

NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells.

https://t.co/eft9VpRLwi

[BioSpace @biospace]

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

https://t.co/mRzTH7dE2B

[BioSpace @biospace]

Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.

https://t.co/wdPCFZPeiX

[BioSpace @biospace]

A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency.

https://t.co/L9dy7XdpSH

[BioSpace @biospace]

All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.

https://t.co/1gSZKNxhKK

[BioSpace @biospace]

Revolution Medicines stole the show at the 2026 ASCO meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso proved the PD-(L)1/VEGF mechanism and Eli Lilly showed that its in vivo CAR T bet is paying off.
https://t.co/W3EwWJDRtX

[BioSpace @biospace]

For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.

https://t.co/OYVJPWgxA4

[BioSpace @biospace]

From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night.

https://t.co/QY7S36a90P

[BioSpace @biospace]

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals.

https://t.co/jhzjQGyJjS

[BioSpace @biospace]

Improved survival on display at ASCO in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its deal streak; and looking ahead to this weekend’s American Diabetes Association meeting.

https://t.co/SmuZlYT3rd